1491-P: Insights from 1,062 Clinicians—Evaluating the Efficacy and Clinical Utility of Empagliflozin-Linagliptin Combination Therapy in T2DM Management
Abstract
Introduction and Objective: The empagliflozin-linagliptin combination is a preferred therapeutic option for type 2 diabetes mellitus (T2DM), addressing glycemic control while providing cardiovascular and renal protection. Its broad-spectrum efficacy makes it essential for managing complex T2DM cases.
Methods: The EMBRACE Survey (Empagliflozin and Linagliptin as Benchmark in Research Adapted for Clinical Experience) was conducted across India from November 8 to December 31, 2024. It included 1,062 clinicians with a cumulative clinical experience of 18,549 man-years (mean: 17 years, SD: 12). The survey evaluated the combination’s efficacy, patient suitability, and clinician preferences using structured questionnaires. Statistical analyses assessed consensus and agreement levels.
Results: Among clinicians, 65% rated the combination as “significantly more effective” in reducing HbA1c than other SGLT-2 and DPP-4 inhibitor combinations, while 29% rated it “slightly more effective.” Weighted scores indicated strong consensus, with a mean score of 122 for efficacy. Patient suitability was highest for individuals with multiple treatment needs (score: 118), cardiovascular or renal protection requirements (112), and uncontrolled HbA1c on monotherapy (109). Indications like weight reduction (10.8%) and discontinuation-prone patients (6.1%) were less frequent. Over 50% of clinicians strongly preferred the combination for its broad efficacy and simplicity, with 51% rating it “extremely…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.